The Pharmacy Times® Lymphoma Resource Center is a comprehensive resource for clinical news and expert insights on treatments for lymphoma, a cancer that begins in cells of the lymph system. Common treatments for lymphoma may involve chemotherapy, medication, radiation therapy, and stem cell transplant.
July 29th 2025
Julio C. Chavez, MD, MS, discusses the distinct pharmacologic profile, clinical activity, and outpatient potential of golcadomide plus rituximab in relapsed/refractory follicular lymphoma, highlighting its selective cereblon modulation, fixed-duration dosing, and promising efficacy in heavily pretreated patients.
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Overcoming Disparities in Multiple Myeloma Treatment: Empowering Pharmacists to Drive Change
1.0 Credit / Health Equity, Diversity & Inclusion, Hematologic Cancer, Hematology, Oncology
View More
Navigating Treatment Evolution in Myelofibrosis: Oncology Pharmacist's Strategies for JAK Inhibitor Optimizati...
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatme...
1.0 Credit / Hematologic Cancer, Oncology
View More
SimulatEd™: Patient-Centered Care to Improve Outcomes in Chronic Lymphocytic Leukemia
1.0 Credit / Hematologic Cancer
View More
Cytokine Release Syndrome With Bispecific Antibodies: A Pharmacist's Guide to Safe Management
1.0 Credit / Hematologic Cancer, Lung Cancer, Oncology
View More
A Pharmacist's Guide to the Safe and Effective Management of BTK and BCL-2 inhibitors in Chronic Lymphocytic L...
1.0 Credit / Hematologic Cancer, Oncology
View More
Closing Gaps in CLL Care: Managed Care Insights and Strategies
1.5 Credit / Hematologic Cancer, Oncology
View More
Guiding Bispecific Antibody Use in Non-Hodgkin Lymphoma: Integrating Evidence and Enhancing Care
1.5 Credits / Hematologic Cancer, Hematology, Oncology
View More
Navigating the New Wave in Targeted Therapies for Acute Myeloid Leukemia: A Focus on IDH and FLT3 Mutations
1.0 Credit / Hematologic Cancer, Oncology
View More
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and...
1.0 Credit / Oncology, Hematology, Hematologic Cancer
View More
Multidisciplinary Perspectives and Patient-Centered Approaches in Newly Diagnosed Multiple Myeloma
1.5 Credits / Hematologic Cancer, Oncology, Hematology
View More
Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based R...
1.5 Credits / Hematologic Cancer, Hematology, Oncology
View More
Beyond Chimeric Antigen Receptor T-Cell Therapy: Comprehensive Approaches for Community Oncology Practices in ...
0.75 Credit / Oncology, Hematologic Cancer, Hematology
View More
JAK(i) of All Trades: Navigating Myelofibrosis Treatment and Safety in Community Oncology Practice
0.75 Credit / Oncology, Hematologic Cancer, Hematology
View More
PBM Challenges and the Evolving Role of Oncology Pharmacists in Community Practices
0.75 Credit / Oncology, Law
View More
Advancing Chronic Lymphocytic Leukemia Treatment in the Community: Practical Updates and Clinical Pearls for O...
0.75 Credit / Oncology, Hematologic Cancer, Hematology
View More
Discipline Decoded: Navigating Pharmacy Law and Disciplinary Cases (Pharmacy Technician Credit)
1.0 Credit / General Pharmacy, Law
View More
Discipline Decoded: Navigating Pharmacy Law and Disciplinary Cases
1.0 Credit / General Pharmacy, Law
View More
Personalizing Treatment in Relapsed/Refractory Multiple Myeloma: The Evolving Role of Antibody-Drug Conjugates...
1.0 Credits / Hematologic Cancer, Oncology
View More
Securing the Supply Chain: The Pharmacists’ Role in DSCSA Compliance
1.0 Credit / Law
View More
FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
January 28th 2023The FDA has approved pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma following at least 2 lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.
Read More
Expert: Unmet Need for Accessible, Effective, Tolerable Therapy for Older Patients With R/R DLBCL
December 13th 2022Based on real-world outcomes, there is an unmet need for an effective therapy to be used among patients aged 75 years or older with relapsed/refractory diffuse large B-cell lymphoma.
Read More